| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
NS-398 [also called NS 398, N-(2-cyclohexyloxy-4-nitrophenyl)methane sulfonamide] is a novel, highly potent and selective inhibitor of cyclooxygenase-2 (COX-2) that is used as a non-steroidal an-inflammatory agent with analgesic and antipyretic effects. The IC50 values for human recombinant COX-1 and -2 are 75 and 1.77 μM, respectively, which means the COX-1 activity is completely unaffected by 75 μM NS-398, whereas the COX-2 activity was concentration-dependently inhibited with the IC50 value being 1.77 μM. NS-398 inhibits proliferation and induces apoptosis in human osteosarcoma cells via downregulation of the survivin pathway. NS-398-enhanced apoptosis of esophageal carcinoma cell EC9706 by adjusting expression of survivin and caspase-3.
| ln Vitro |
With an IC50 of 3.8 μM and no effect on COX-1 at 100 μM, NS-398 is a nonsteroidal anti-inflammatory drug that specifically inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity. [1]. In sheep seminal vesicle microsomes, NS-398 weakly inhibits PG endoperoxide synthase activity (IC50: 11 μM)[2].
|
||
|---|---|---|---|
| ln Vivo |
Rats with an ED30 of 1.14 mg/kg showed dose-dependent inhibition of paw edema when treated with NS-398 (0.5-10 mg/kg, po), and this treatment was effective in managing adjuvant arthritis (ED30, 4.69 mg/kg). In rats, it has an antipyretic effect (ED50, 1.84 mg/kg) and a dose-dependent analgesic effect (ED50, 1.65 mg/kg). With an ED50 of 8.2 mg/kg, NS-398 suppresses the writhing response brought on by acetic acid in mice[2].
|
||
| Animal Protocol |
|
||
| References |
[1]. Futaki N, et al. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins. 1994 Jan;47(1):55-9.
[2]. Futaki N, et al. NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen Pharmacol. 1993 Jan;24(1):105-10 |
| Molecular Formula |
C13H18N2O5S
|
|
|---|---|---|
| Molecular Weight |
314.36
|
|
| CAS # |
123653-11-2
|
|
| Related CAS # |
|
|
| SMILES |
CS(=O)(NC1=CC=C([N+]([O-])=O)C=C1OC2CCCCC2)=O
|
|
| Synonyms |
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (7.95 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 1.67 mg/mL (5.31 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.67 mg/mL (5.31 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1811 mL | 15.9053 mL | 31.8107 mL | |
| 5 mM | 0.6362 mL | 3.1811 mL | 6.3621 mL | |
| 10 mM | 0.3181 mL | 1.5905 mL | 3.1811 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|---|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
